Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.4
5.2
Journals
Cancers
Special Issues
State-of-the-Art Treatment on Chemotherapy and Immunotherapy for Urological Cancer
share announcement

State-of-the-Art Treatment on Chemotherapy and Immunotherapy for Urological Cancer

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Tumor Microenvironment".

Deadline for manuscript submissions: 31 December 2024 | Viewed by 1447

Special Issue Editors

Prof. Dr. Kouji Izumi

E-Mail Website
Guest Editor
Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, 13-1 Takara-Machi, Kanazawa, Ishikawa 920-8641, Japan
Interests: prostate cancer; androgen receptor; castration-resistant prostate cancer; immuno-oncology
Special Issues, Collections and Topics in MDPI journals
Dr. Hiroshi Yaegashi

E-Mail Website
Guest Editor
Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, 13-1 Takara-Machi, Kanazawa, Ishikawa 920-8641, Japan
Interests: prostate cancer

Special Issue Information

Dear Colleagues,

The recent progress of medical oncology in urological cancer is remarkable. Immune checkpoint inhibitors, antibody–drug conjugates, and molecular targeting agents for kidney and urothelial cancer have dramatically changed the treatment system and philosophy. Radioligand therapy for prostate cancer is a promising modality and is now used worldwide. Although these novel concepts of treatment strategies contribute to the improvement of patient’s survival and quality of life, most patients with advanced cancer still cannot be cured, and the cancer cells at metastatic sites are hardly eradicated. In addition, urological rare cancers such as urachal cancer, penile cancer, adrenal cancer, and retroperitoneal sarcoma still have no standard therapy. This Special Issue calls for clinical studies and reviews of state-of-the-art treatments for urological cancers. Basic research dissecting biological, pathological, and pharmacological mechanisms for the development of novel treatments in urological cancers is also welcome.

Prof. Dr. Kouji Izumi
Dr. Hiroshi Yaegashi
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • chemotherapy
  • immunotherapy
  • antibody–drug conjugate
  • radioligand therapy
  • urological cancer
  • prostate cancer
  • kidney cancer
  • urothelial cancer
  • urachal cancer
  • penile cancer
  • adrenal cancer
  • sarcoma
  • clinical trial
  • basic research

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

12 pages, 1941 KiB  
Article
Enzalutamide versus Abiraterone Plus Prednisolone for Nonmetastatic Castration-Resistant Prostate Cancer: A Sub-Analysis from the ENABLE Study for PCa
by Koji Mita, Kouji Izumi, Akihiro Goriki, Ryo Tasaka, Tomoya Hatayama, Takashi Shima, Yuki Kato, Manabu Kamiyama, Shogo Inoue, Nobumichi Tanaka, Seiji Hoshi, Takehiko Okamura, Yuko Yoshio, Hideki Enokida, Ippei Chikazawa, Noriyasu Kawai, Kohei Hashimoto, Takashi Fukagai, Kazuyoshi Shigehara, Shizuko Takahara, Yoshifumi Kadono and Atsushi Mizokamiadd Show full author list remove Hide full author list
Cancers 2024, 16(3), 508; https://doi.org/10.3390/cancers16030508 - 24 Jan 2024
Viewed by 1135
Abstract
Enzalutamide (ENZ) and abiraterone plus prednisolone (ABI) can improve the survival of patients with castration-resistant prostate cancer (CRPC). However, the agent that is more effective against nonmetastatic CRPC remains unclear. To evaluate the agent that can be used as the first-line treatment for [...] Read more.
Enzalutamide (ENZ) and abiraterone plus prednisolone (ABI) can improve the survival of patients with castration-resistant prostate cancer (CRPC). However, the agent that is more effective against nonmetastatic CRPC remains unclear. To evaluate the agent that can be used as the first-line treatment for CRPC, an investigator-initiated, multicenter, randomized controlled trial (ENABLE Study for PCa) including both metastatic and nonmetastatic CRPC was conducted in Japan. The prostate-specific antigen (PSA) response rate, overall survival, some essential survival endpoints, and safety of patients with nonmetastatic CRPC were also analyzed. In this subanalysis, 15 and 26 patients in the ENZ and ABI arms, respectively, presented with nonmetastatic CRPC. There was no significant difference in terms of the PSA response rate between the ENZ and ABI arms (80% and 64%, respectively; p = 0.3048). The overall survival did not significantly differ between the two arms (HR: 0.68; 95% CI: 0.22–2.14, p = 0.5260). No significant differences were observed in terms of radiographic progression-free survival and cancer-specific survival between the ENZ and ABI arms (HR: 0.81; 95% CI: 0.35–1.84; p = 0.6056 and HR: 0.72; 95% CI: 0.19–2.73; p = 0.6443, respectively). Only four and six patients in the ENZ and ABI arms, respectively, had ≥grade 3 adverse events. ABI and ENZ had similar efficacy and safety profiles in patients with nonmetastatic CRPC. Full article
(This article belongs to the Special Issue State-of-the-Art Treatment on Chemotherapy and Immunotherapy for Urological Cancer)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop